OncoMatch

OncoMatch/Clinical Trials/NCT07679061

First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)

Is NCT07679061 recruiting? Yes, currently enrolling (Jul 2026). Studying Nivolumab plus ipilimumab for unresectable hepatocellular carcinoma.

RecruitingBristol-Myers SquibbNCT07679061Data as of Jul 2026Location: Japan

Treatment: Nivolumab plus ipilimumabThis study looks at how a combination of two medicines, nivolumab and ipilimumab, is used to treat people with advanced liver cancer that cannot be removed by surgery. The study will follow adults receiving this treatment in routine medical care in Japan to understand how safe it is, how well it works, and how it is used in standard clinical practice.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Immunotherapy

Nivolumab plus ipilimumab

Cancer type

Hepatocellular Carcinoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: immuno-oncology treatment

Prior immuno-oncology treatment

Cannot have received: systemic drug therapy for uHCC

Exception: Participants who relapsed more than 6 months after completion of postoperative adjuvant therapy are eligible; participants who received lenvatinib in combination with TACE are eligible if the treating physician determined they were eligible for TACE; participants are excluded if TACE eligibility at the time of lenvatinib initiation is unclear

Participants who have not received prior systemic drug therapy for uHCC

Cannot have received: liver transplant

Prior liver transplant

Lab requirements

Liver function

child-pugh class a (total score 5-6)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT07679061 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify